Plasma Metabolomics in Liver Tumor Patients and its Predictive Performance for Postoperative Disease-free Survival Assessment

Abstract

Introduction: Liver surgery still remains the only curative treatment for primary (HCC, CCC) and secondary (CRCLM) liver cancer. However, patients show significant differences in terms of postoperative disease-free status and recurrences often occur within first six months after surgery. There is emerging evidence that tumor biology is a huge and heterogenous field with many aspects and not easily comprehensible. Therefore, we try to elucidate differences in tumor biology and its impact on disease-free survival in this prospective cohort using an unbiased metabolomics approach.